- Home
- KALV vs FFC Comparison
KALV vs FFC Comparison
Compare KALV & FFC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KALV
- FFC
- Stock Information
- Founded
- KALV N/A
- FFC 1983
- Country
- KALV United States
- FFC United States
- Employees
- KALV N/A
- FFC N/A
- Industry
- KALV Biotechnology: Pharmaceutical Preparations
- FFC Trusts Except Educational Religious and Charitable
- Sector
- KALV Health Care
- FFC Finance
- Exchange
- KALV Nasdaq
- FFC Nasdaq
- Market Cap
- KALV 642.3M
- FFC 741.9M
- IPO Year
- KALV N/A
- FFC N/A
- Fundamental
- Price
- KALV $14.31
- FFC $16.45
- Analyst Decision
- KALV Strong Buy
- FFC
- Analyst Count
- KALV 9
- FFC 0
- Target Price
- KALV $26.29
- FFC N/A
- AVG Volume (30 Days)
- KALV 2.0M
- FFC 164.1K
- Earning Date
- KALV 07-10-2025
- FFC 01-01-0001
- Dividend Yield
- KALV N/A
- FFC 6.79%
- EPS Growth
- KALV N/A
- FFC N/A
- EPS
- KALV N/A
- FFC N/A
- Revenue
- KALV N/A
- FFC N/A
- Revenue This Year
- KALV N/A
- FFC N/A
- Revenue Next Year
- KALV $347.19
- FFC N/A
- P/E Ratio
- KALV N/A
- FFC N/A
- Revenue Growth
- KALV N/A
- FFC N/A
- 52 Week Low
- KALV $7.30
- FFC $11.90
- 52 Week High
- KALV $16.32
- FFC $14.96
- Technical
- Relative Strength Index (RSI)
- KALV 58.58
- FFC 65.55
- Support Level
- KALV $11.10
- FFC $16.40
- Resistance Level
- KALV $16.32
- FFC $16.58
- Average True Range (ATR)
- KALV 1.10
- FFC 0.11
- MACD
- KALV 0.36
- FFC 0.01
- Stochastic Oscillator
- KALV 68.95
- FFC 81.33
About KALV KalVista Pharmaceuticals Inc.
KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.
About FFC Flaherty & Crumrine Preferred and Income Securities Fund Incorporated
Flaherty & Crumrine Preferred and Income Securities Fund Incorporated is a diversified, closed-end management investment company. The fund's investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. It invests in a diversified portfolio of preferred securities.